BSD Medical Corporation, today reported the successful promotion of the MicroThermX® Microwave Ablation System (MicroThermX) at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) conference in Barcelona, Spain. Terumo Europe NV (Terumo), a wholly owned subsidiary of Terumo Corporation, used CIRSE as the main launching pad to showcase BSD’s MicroThermX as an integral part of its branded Interventional Oncology Solutions (IOS). CIRSE is the world’s largest and most prestigious conference in the field of minimally invasive image-guided therapies.
Hundreds of physicians attended the MicroThermX symposium, including key physician opinion leaders throughout Europe. Terumo, the leader in interventional oncology, now features MicroThermX as one of the key products in its interventional oncology portfolio: .
“We see tremendous opportunity for fast adoption in Europe for our MicroThermX Microwave Ablation System because the structure of the healthcare systems in the area is focused on cost-effective solutions and faster adoption of new superior technology,” said Harold Wolcott, BSD President and CEO. “The physician response and interest in the MicroThermX far exceeded our expectations. We are very pleased with our relationship with Terumo.”